Results 221 to 230 of about 78,152 (242)

Modeling the synergy between HSV-2 and HIV and potential impact of HSV-2 therapy

Mathematical Biosciences, 2013
Mounting evidence indicates that genital HSV-2 infection may increase susceptibility to HIV infection and that co-infection may increase infectiousness. Accordingly, antiviral treatment of people with HSV-2 may mitigate the incidence of HIV in populations where both pathogens occur. To better understand the epidemiological synergy between HIV and HSV-2,
Feng, Zhilan, Qiu, Zhipeng, Sang, Zi, Lorenzo, Christina, Glasser, John   +4 more
openaire   +3 more sources

Varicella-zoster virus expressing HSV-2 glycoproteins B and D induces protection against HSV-2 challenge

Vaccine, 2004
A recombinant Oka (ROka) varicella-zoster virus (VZV) vaccine was constructed that expresses herpes simplex virus type 2 (HSV-2) glycoproteins B (gB) and D (gD). Guinea pigs received one of four inocula: (a). uninfected cells, (b). recombinant Oka VZV infected cells, (c).
Thomas C, Heineman, Lesley, Pesnicak, Mir A, Ali, Tammy, Krogmann, Nancy, Krudwig, Jeffrey I, Cohen   +5 more
openaire   +2 more sources

Safety and immunogenicity of long HSV-2 peptides complexed with rhHsc70 in HSV-2 seropositive persons

Vaccine, 2011
HSV-2, the primary causative agent of genital herpes, establishes latency in sensory ganglia and reactivates causing recurrent lesions and viral shedding. Induction or expansion of CD4(+) and CD8(+) T cell responses are expected to be important for a successful therapeutic vaccine against HSV-2.
Anna, Wald, David M, Koelle, Kenneth, Fife, Terri, Warren, Kenneth, Leclair, Roman M, Chicz, Stephen, Monks, Daniel L, Levey, Cristina, Musselli, Pramod K, Srivastava   +9 more
openaire   +2 more sources

Development of a microneutralization assay for HSV-2

Journal of Virological Methods, 2021
Plaque Reduction Neutralization Test (PRNT) is the standard assay used for measuring neutralizing antibody responses to Herpes simplex virus type-2 (HSV-2). The PRNT is a cumbersome, time-consuming and laborious assay. The development of a faster, high throughput microneutralization assay (MNA) for HSV-2 viruses carried out in a 96-well format will ...
Melanie S. Horton, Michael Minnier, Scott Cosmi, Kara Cox, Jennifer Galli, Jessica Peters, Nicole Sullivan, Brian Squadroni, Aimin Tang, Arthur Fridman, Dai Wang, Zhifeng Chen, Kalpit A. Vora   +12 more
openaire   +2 more sources

Helicase–Primase Inhibitor Pritelivir for HSV-2 Infection

New England Journal of Medicine, 2014
Pritelivir, an inhibitor of the viral helicase-primase complex, exhibits antiviral activity in vitro and in animal models of herpes simplex virus (HSV) infection. We tested the efficacy and safety of pritelivir in otherwise healthy persons with genital HSV-2 infection.We randomly assigned 156 HSV-2-positive persons with a history of genital herpes to ...
Sonia, Burrel, Caroline, Rouard, David, Boutolleau   +2 more
openaire   +4 more sources

Clinical characteristics of acute HSV-2 retinal necrosis

American Journal of Ophthalmology, 2004
To report the clinical features and evaluate the visual outcome of eleven cases of herpes simplex virus-2 (HSV-2) related acute retinal necrosis syndrome (ARN).Retrospective interventional case series.Twelve eyes of eleven patients from two European centers, diagnosed with HSV-2 related acute retinal necrosis syndrome were retrospectively reviewed ...
Tran, Thao, Stanescu, Dinu, Caspers, Laure, Rozenberg, Flore, Liesnard, Corinne, Gaudric, Alain, Lehoang, Phuc, Bodaghi, Bahram   +7 more
openaire   +2 more sources

Anti HSV-2 properties of amniotic fluid.

Microbiologica, 1988
Some antiviral properties of amniotic fluid (AF) were studied. A close relationship between maternal blood and AF antiviral antibodies was seen. Substances other than antibodies which could have an effect on viruses were assumed to be present in AF. Using HSV2 as a model, we found a virus-neutralizing activity in 6 out of 7 specimens studied which does
ROSSANO F, RIZZO, Antonietta, SANGES MR, CIOFFI S, TRIPODI V.   +4 more
openaire   +2 more sources

VAGINAL IMMUNITY IN THE HSV-2 MOUSE MODEL

International Reviews of Immunology, 2003
Herpes simplex virus type 2 (HSV-2) is a sexually transmitted pathogen that infects the genital tract. Efforts to develop vaccines to protect women against this and other sexually transmitted pathogens would be facilitated by a better understanding of the immune mechanisms that protect the female reproductive tract against such infections.
Margaret B, Parr, Earl L, Parr
openaire   +2 more sources

Development of a therapeutic vaccine for HSV-2

Vaccine, 2005
A therapeutic vaccine for genital herpes is clearly needed. Vaccines recently developed for HSV-2 in humans have been aimed at eliciting CD4+ T cell responses and neutralizing antibody responses to two HSV-2 glycoproteins (gB and gD). These vaccines have had no therapeutic effect against HSV-2 in human clinical trials.
openaire   +2 more sources

Seroprevalence of HSV-2 in Hungary and comparison of the HSV-2 prevalence of pregnant and infertile women

Acta Microbiologica et Immunologica Hungarica, 2008
Herpes simplex virus type 2 infection is a quite common but frequently asymptomatic, therefore undiagnosed condition. Genital HSV-2 infection may cause neonatal herpes, enhances HIV transmission and may play a role in infertility. To evaluate the prevalence of HSV-2 in Hungary we tested 2500 serum samples for the presence of anti-HSV-2 IgG by ELISA ...
Hettmann, Andrea, Gerle, Borbála, Barcsay, Erzsébet, Csiszár, Csenge, Takács, Mária   +4 more
openaire   +3 more sources